March 2016, Vol 9, Seventh Annual Payers' Guide
Yondelis (Trabectedin) Approved for the Treatment of Unresectable or Metastatic Soft-Tissue Sarcomas
Sarcomas, a group of malignant tumors that develop in soft tissue and bone, can affect any part of the body but most often occur in the abdomen, arms, and legs. Soft-tissue sarcomas typically form in the muscle, cartilage, fat, blood vessels, nerves, and other connective or supportive tissues, including the tendons and joint linings.
Vyvanse (Lisdexamfetamine Dimesylate): First FDA-Approved Drug for the Treatment of Adults with Binge-Eating Disorder
Varubi (Rolapitant) Approved for the Prevention of Delayed-Onset Chemotherapy-Induced Nausea and Vomiting
Tagrisso (Osimertinib) Approved for Patients with Non–Small-Cell Lung Cancer and the EGFR T790M Mutation
Lung cancer is one of the most frequently diagnosed cancers, and is the leading cause of cancer-related mortality worldwide and in the United States among men and women. Non–small-cell lung cancer (NSCLC) is the most common form of the disease, accounting for approximately 85% of all lung cancer cases.
ProAir RespiClick (Albuterol Sulfate): First Breath-Actuated Inhaler Approved for the Treatment or Prevention of Bronchospasm
Opdivo (Nivolumab), a PD-1 Inhibitor, Receives New Indications for Melanoma, NSCLC, and Renal-Cell Carcinoma
Lung cancer, melanoma, and renal-cell carcinoma represent significant burdens for patients and for the healthcare system. In light of the high morbidity and mortality associated with these malignancies and the quality-of-life challenges, there is a marked need for additional therapeutic options that improve outcomes for patients with melanoma, non–small-cell lung cancer (NSCLC), or renal-cell carcinoma.
Odomzo (Sonidegib), a Hedgehog Pathway Inhibitor, FDA Approved for the Treatment of Patients with Locally Advanced Basal-Cell Carcinoma
Basal-cell carcinoma is the most common type of skin cancer, accounting for approximately 80% of nonmelanoma skin cancers. More than 2.8 million new cases of basal-cell carcinoma are diagnosed annually in the United States, and 3000 people die from this disease annually.
Iressa (Gefitinib), Oral Tyrosine Kinase Inhibitor, Approved for First-Line Therapy for Patients with Metastatic NSCLC and EGFR Mutation
Cyramza (Ramucirumab) Receives New FDA Indication for Second-Line Treatment of Patients with Metastatic Colorectal Cancer
Cotellic (Cobimetinib) FDA Approved as Part of a Combination for Patients with Advanced Melanoma and a BRAF Mutation
Page 1 of 5
Results 1 - 10 of 43
Results 1 - 10 of 43